Search Results

He is particularly excited by the novel application of PAMs in chronic and neuropathic pain models , including the neuroma model , which is typically opioid-insensitive. Discovering breakthrough results in neuroma pain models via a spontaneous collaboration. This project involves molecular pharmacology in cell models to determine binding sites and mechanisms of allostery, as well as efficacy studies in mouse and rat models of acute and chronic pain.

recurring example: the same molecule promotes opioid antinociception in one context, drives chronic pain the dorsal horn lights up with phospho-ERK in response to opioid, routing through RSK1/2 to stronger pain With a non-selective HSP90 inhibitor given systemically, the brain effect dominates and pain relief is a six-hour feeding window for seven days increased morphine's antinociceptive efficacy in multiple pain models, strongly reduced tolerance and constipation, and completely blocked morphine reward in conditioned

Alex Serafini shares why pain research must start with real-world behavior and models before drilling , Serafini’s vision is bold: build a lab that develops translational models of pain rooted in patient He's equally focused on sex differences in pain processing and the failure of "one-size-fits-all" models Whether it’s challenging legacy targets, redefining preclinical models, or exploring the epigenetic inheritance He aspires to become a physician-scientist, with a focus on translational in vitro and in vivo model

the University of Illinois at Chicago has spent years pulling apart that asymmetry — combining mouse models Her research integrates behavioral pharmacology, ligand-directed signaling, and mouse models of migraine in preclinical models. Her next career step took her to AstraZeneca as a postdoctoral trainee, where she studied animal models Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic

Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics interested in translational innovation Biotech investors and strategic leaders seeking new drug development models Woolf at Boston Children’s Hospital and Harvard Medical School, where he deepened his understanding of pain Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics , a biotech startup focused on targeting supraspinal GPCRs for chronic pain.

During these four sessions, you'll dive into: Advanced pharmacokinetic modeling The Druglike Quality Model to Predict Agonism – October 2, 2025 Premium Members save 25% on enrollment. Classified GPCR News Let’s dive into the Classified GPCR News from February 10th to 16th, 2025 Industry News Pain administration in spinal cord injury GPR37L1 identifies spinal cord astrocytes and protects neuropathic pain Neuroregeneration , EPSC , GLT-1 , GPR37L1 , SPM , astrocytes , maresin 1 , microglia , nerve injury , neuropathic pain

agonist depending on receptor tone Quantitative pharmacology as rescue operation — using operational models A quantitative model can turn an artifact into pharmacology. Early in her postdoc, Dr. The resolution came not from a new experiment but from a model — protean agonism, as Kenakin had just in Bouvier's lab 05:30 — The side project that became the real work 08:22 — Protean agonism and the model So that is why I got so into the models — in order to salvage my project."

From her early doubts to designing preclinical models of fentanyl and xylazine overdose, she reflects The methods used to measure respiratory depression in live models. But loss has a way of sharpening focus—friends lost to overdose brought the opioid epidemic into painful shut down breathing through different mechanisms—work that blends receptor pharmacology, preclinical models

conjugates to target GPCRs, with a focus on receptors relevant for treating osteoporosis, diabetes, and pain During that time, I investigated the effect of lung cancer-related mutations in the GAIN domain of the elucidating the molecular basis of membrane protein signalling using quantitative assays and molecular modelling

Nigel Bunnett at the NYU Pain Research Center as a postdoctoral researcher. focuses on investigating GPCR signaling and trafficking in the context of inflammation and chronic pain Next Steps Badr will continue focusing his research on GPCRs involved in pain and inflammation during Badr shared his passion for GPCR signalling and regulation, specifically in the context of pain and inflammation

biased agonism, and incorporates computational and mathematical modelling, structural and chemical biology , molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease encompassing neurological and psychiatric disorders, cardiovascular disease, obesity, diabetes, chronic pain The conversation ended with Arthur's ongoing research and his development of a new operational model. model for allosteric modulation, emphasizing the balance between mechanism and empiricism.

Can models predict drug outcomes? Jens Carlsson shares how GPCR modeling is moving from explanation to real prediction in drug discovery . << Back to podcast list Strategic Partner(s) Model. Jens Carlsson What if models didn’t just explain the past — but could truly predict what comes next? Yamina Berchiche to share his unconventional journey from aspiring engineer to GPCR modeler.

conjugates to target GPCRs, with a focus on receptors relevant for treating osteoporosis, diabetes, and pain

Cancer Research, 2014) and GPCRs (Feigin, et al., PNAS, 2014) in breast cancer pathogenesis, using mouse models Mike also spoke about his initial struggles during his Ph.D., such as a difficult model system and a about cancer biology led him to transition into using mouse models. asked about his move from in vitro to in vivo work, and Mike explained that he wanted to use better models Yamina proposed further exploration of dosage and length of treatment in a mouse model and suggested

neurons), Vollum Institute Portland (visiting scientist with Ed McCleskey, sensory neuron properties); Pain

Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential April 1 - 3, 2025 | 2nd Peptide-Based Therapeutics Summit - USA April 2 - 3, 2025 | New therapeutic modalities larval growth and embryonic development in the multivoltine strain of Bombyx more Profiling Allosteric Modulators GPCRs in Neuroscience Cortical astrocyte activation triggers meningeal nociception and migraine-like pain β-arrestin-1/endothelin axis in human ovarian fibroblasts Methods & Updates in GPCR Research Histamine-modulated

passion, I recently started a postdoctoral fellowship to study the role of GPCRs in the mechanisms of pain

heterodimers and the limits of current characterization tools Structural biology of RAMPs - allosteric modulation Each of the three RAMPs can pair with a given receptor to produce a distinct complex - different ligand structurally obvious, making ligand selectivity considerably harder to engineer than a direct-contact model The scientists who persist, in her framing, are not the ones who feel less pain from those setbacks, She has gained experience from working in academia and at GSK as an industrial trainee.

His research focuses on novel paradigms of drug action at GPCRs, particularly allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural and chemical biology , molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease encompassing neurological and psychiatric disorders, cardiovascular disease, obesity, diabetes, chronic pain

His research focuses on novel paradigms of drug action at GPCRs, particularly allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural and chemical biology , molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease encompassing neurological and psychiatric disorders, cardiovascular disease, obesity, diabetes, chronic pain

, and confronting the true-negatives problem that quietly breaks so many published models. True negatives quietly wreck biological models. Most published models rely on inferred negatives — genes or molecules assumed inactive by convenience , the model's predictions changed radically. 37:01 Reading GPCR signaling dynamics with computational models 39:53 Generative models, scoring functions

For this, we have worked in three main areas: the regulation of G protein-coupled receptor signaling including structural biology and proteomics, molecular biology and biochemical enzymology, primary and model cell culture, and transgenic, knockout, knock-in and conditional models of mouse physiology and behavior

For this, we have worked in three main areas: the regulation of G protein-coupled receptor signaling including structural biology and proteomics, molecular biology and biochemical enzymology, primary and model cell culture, and transgenic, knockout, knock-in and conditional models of mouse physiology and behavior

For this, we have worked in three main areas: the regulation of G protein-coupled receptor signaling including structural biology and proteomics, molecular biology and biochemical enzymology, primary and model cell culture, and transgenic, knockout, knock-in and conditional models of mouse physiology and behavior

For this, we have worked in three main areas: the regulation of G protein-coupled receptor signaling including structural biology and proteomics, molecular biology and biochemical enzymology, primary and model cell culture, and transgenic, knockout, knock-in and conditional models of mouse physiology and behavior

Before focusing on the development of innovative mathematical modeling and simulation methods for drug They explored the potential of merging mathematical models with biology, the complexities of GPCRs within Integrating Mathematical Models and Biology: A Fascinating Discussion Yamina and Aurelien Rizk had a conversation about the importance of merging mathematical models and biology. and relevance of mathematical models in systems biology and pharmacology.

Alessandro Nicoli shares how he models olfactory GPCRs with AlphaFold, mentors students, and builds science “AlphaFold gave us a face to those proteins… now we have 400 models to start with.” – Alessandro Nicoli Build predictive models to discover new ligands . About Alessandro Nicoli Alessandro Nicoli is currently a PhD student in the Molecular Modeling group Stefano Moro, where he worked on integrated Nuclear magnetic resonance (NMR) and computational modeling

Fellowship to develop novel methods of synthesizing 2 -imidazoline scaffolds to be used as proteasome modulators Klein's lab where she helped to investigate the role of various ATP-sensitive potassium channels in pain Lauren Slosky, she is working to understand the mechanism by which a new class of biased allosteric modulators

biology into traditionally pharmacology-driven GPCR programs and worked across migraine, cardiovascular, pain several GPCRs including GABA B and carboxylic acid receptors, and discovery of a prostaglandin EP4 modulator it combined high receptor density with practical availability, illustrating how pragmatic choices in model

to the University of Oxford on a 4-year Wellcome Trust Scholarship in Neuroscience, through which I gained I work with invertebrate animal models (mainly D. melanogaster) and in vitro techniques to pick apart adhesion GPCRs, and extends to the development of novel screening approaches to identify pharmacological modulators